As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...

Shares of Amgen AMGN fell by more than 5% on Wednesday after it reported top-line data on two different drugs in the ...

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...

Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...

Medicines the company is developing for eczema and myasthenia gravis met their objectives in Phase 3 trials. But analysts weren’t convinced they can compete with available alternatives.

Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...

Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in ...

The BLA submission for nipocalimab marks a significant advancement in treating generalized myasthenia gravis, showing improved MG-ADL scores in clinical trials.

The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.

Amgen (AMGN) shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and ...